Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study

References

• Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd edn. Washington, DC: American Psychiatric Association, 2004
   Google Scholar
• Wessels T, Grunler D, Bunk C, et al. Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004. Psychiatr Q 2007;78:91-9
   PubMed Web of Science ®Google Scholar
• Saraceno B. The WHO World Health Report 2001 on mental health. Epidemiologia Psichiatria Sociale 2002;11:83-7
   PubMedGoogle Scholar
• Theme-Filha M, Szwarcwald CL, Borges de Souza-Júnior PR. Socio-demographic characteristics, treatment coverage, and self-rated health of individuals who reported six chronic diseases in Brazil, 2003. Cad Saude, Publica, Rio de Janeiro 2005;21(Suppl):S43-53
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007;68(Suppl 1):12-19
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals I. Risperdal® (risperidone) tablets, oral solution, orally disintegrating tablets. Last updated August 2012. Available at: http://www.risperdal.com/prescribing.html [Last accessed 18 October 2013]
   Google Scholar
• Janssen PA, Niemegeers CJ, Awouters F, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-93
   PubMed Web of Science ®Google Scholar
• Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-70
   PubMed Web of Science ®Google Scholar
• Ortho-McNeill-Janssen Pharmaceuticals I. Invega® (paliperidone) extended-release tablets [US package insert]. Last updated June 2011. Available at: http://invega.com/prescribing-information [Last accessed 18 October 2013]
   Google Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burns T, Morosini P, et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009;25:325-38
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, Maryland: National Institute of Mental Health, 1976
   Google Scholar
• Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
   Google Scholar
• Chouinard G, Ross-Chouinard J, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233
   Web of Science ®Google Scholar
• Gharabawi GM, Bossie CA, Lasser RA, et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res 2005;77:119-28
   PubMed Web of Science ®Google Scholar
• Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-65
   PubMed Web of Science ®Google Scholar
• Nicholl D, Nasrallah H, Nuamah I, et al. Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Curr Med Res Opin 2010;26:1471-84
   PubMed Web of Science ®Google Scholar
• Kim EY, Chang SM, Shim JC, et al. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Curr Med Res Opin 2013;29:1231-40
   PubMed Web of Science ®Google Scholar
• Schmauss M, Jukić V, Siracusano A, et al. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin 2012;28:1395-404
   PubMed Web of Science ®Google Scholar
• Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25:3130-9
   Google Scholar
• Okamoto LJ, Noonan M, De Boisblanc BP, Kellerman DJ. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996;76:455-61
   Google Scholar
• Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of outcomes. Qual Life Res 2005;14:285-95
   Google Scholar
• Reine G, Lancon C, Di Tucci S, et al. Depression and subjective quality of life in chronic phase schizophrenia. Psychopathology 2005;38:320-6
   Google Scholar
• Karow A, Moritz S, Lambert M, et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38:320-6
   Google Scholar
• Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
   PubMed Web of Science ®Google Scholar
• Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21
   PubMed Web of Science ®Google Scholar
• Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-65
   PubMed Web of Science ®Google Scholar